Preclinical toxicity and efficacy study of a 14-day schedule of oral 5- iodo-2-pyrimidinone-2'-deoxyribose as a prodrug for 5-iodo-2'-deoxyuridine radiosensitization in U251 human glioblastoma xenografts

Clinical Cancer Research

Volumn 6, Issue 4, 2000, Pages 1468-1475

  Kinsella, Timothy J ^a,c   Vielhuber, Kathleen A ^a   Kunugi, Keith A ^a   Schupp, Jane ^a   Davis, Thomas W ^a   Sands, Howard ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SuperGen Pharmaceutical Inc   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 IODO 2 PYRIMIDINONE 2' DEOXYRIBOSE; DNA; IDOXURIDINE; PRODRUG; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TUMOR; CANCER RADIOTHERAPY; CANCER TRANSPLANTATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; TOXICITY TESTING;

ADMINISTRATION, ORAL; ALDEHYDE OXIDASE; ALDEHYDE OXIDOREDUCTASES; ANIMALS; BODY WEIGHT; DNA; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IDOXURIDINE; LIVER EXTRACTS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PRODRUGS; PYRIMIDINE NUCLEOSIDES; RADIATION-SENSITIZING AGENTS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0034050958     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Kinsella, T. J. An approach to the radiosensitization of human tumors. Cancer J. Sci. Am., 2: 184-193, 1996.
2. McGinn, C. J., Shewach, D. S., and Lawrence, T. S. Radiosensitizing nucleosides. J. Natl. Cancer Inst., 88: 1193-1203, 1996.
3. Miller, E. M., Fowler, J. F., and Kinsella, T. J. Linear-quadratic analysis of radiosensitization by halogenated pyrimidines. I. Radiosensitization of human colon cancer cells by iododeoxyuridine. Radiat. Res., 131: 81-89, 1992.
4. Lawrence, T. S., Davis, M. A., Maybaum, J., Stetson, P. L., and Ensminger, W. D. The dependence of halogenated pyrimidine incorporation and radiosensitization on the duration of drug exposure. Int. J. Radiat. Oncol. Biol. Phys., 18: 1393-1398, 1990.
5. Kinsella, T. J., Dobson, P. P., Mitchell, J. B., and Fornace, A. J. Enhancement of x-ray induced DNA damage by pretreatment with halogenated pyrimidine analogs. Int. J. Radiat. Oncol. Biol. Phys., 13: 733-739, 1987.
6. Fornace, A. J., Dobson, P. P., and Kinsella, T. J. Enhancement of radiation damage in cellular DNA following unifilar substitution with iododeoxyuridine. Int. J. Radiat. Oncol. Biol. Phys., 18: 873-878, 1990.
7. Lawrence, T. S., Davis, M. A., Maybaum, J., Stetson, P. L., and Ensminger, W. D. The effect of single versus double stranded substitution on halogenated pyrimidine-induced radiosensitization and DNA strand breakage in human tumor cells. Radiat. Res., 123: 192-198, 1991.
8. Wang, Y., and Iliakis, G. Effects of 5′-iododeoxyuridine on the repair of radiation induced potentially lethal damage, interphase chromatin breaks, and DNA double strand breaks in Chinese hamster ovary cells. Int. J. Radiat. Oncol. Biol. Phys., 23: 353-360, 1992.
9. Schultz, C., Gaffney, D., Lindstrom, M., and Kinsella, T. J. Iododeoxyuridine radiosensitization of human glioblastoma cells exposed to acute and chronic gamma irradiation: mechanistic implications and clinical relevance. Cancer J. Sci. Am., 1: 151-161, 1995.
10. Rodriquez, R., Ritter, M. A., Fowler, J. F., and Kinsella, T. J. Kinetics of cell labeling and thymidine replacement after continuous infusion of halogenated pyrimidines in vivo. Int. J. Radiat. Oncol. Biol. Phys., 29: 105-113, 1994.
11. Fowler, J. F., and Kinsella, T. J. The limiting radiosensitization of tumors by S-phase sensitizers. Br. J. Cancer, 74 (Suppl.) 27: 294-296, 1996.
12. Urtasun, R., Kinsella, T., Farnam, N., DelRowe, J., Lester, S., and Fulton, D. Survival improvement in anaplastic astrocytoma combining external radiation with halogenated pyrimidines: Final report of RTOG 86-12, Phase I-II study. Int. J. Radiat. Oncol. Biol. Phys., 36: 1163-1167, 1996.
13. Prados, M., Scott, C., Rotman, M., Rubin, P., Murray, K., Sause, W., Asbell, S., Comis, R., Curran, W., Nelson, J., Davis, R., Levin, V., Lamborn, K., and Phillips, T. Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: A retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group Trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma. Int. J. Radiat. Oncol. Biol. Phys., 40: 653-659, 1998.
14. Eisbruch, A., Robertson, J. M., Johnston, C. M., Tworek, J., Reynolds, K. R., Roberts, J. A., and Lawrence, T. S. Bromodeoxyuridine alternating with radiation for advanced uterine cervix cancer: A Phase I and drug incorporation study. J. Clin. Oncol., 17: 31-40, 1999.
15. Epstein, A. H., Lebovics, R. S., Goffman, T., Teague, D., Fuetsch, E. S., Glatstein, E., Okunieff, P., and Cook, J. A. Treatment of locally advanced cancer of the head and neck with 5′-iododeoxyuridine and hyperfractionated radiation therapy: measurement of cell labeling and thymidine replacement. J. Natl. Cancer Inst., 86: 1775-1780, 1994.
16. Chang, A. I., Collins, J. M., Speth, P. A. J., Smith, R., Walton, L., Begley, M. G., Glatstein, E., and Kinsella, T. J. A Phase I study of intra-arterial iodocleoxyuridine in patients with colorectal liver metastases. J. Clin. Oncol., 6: 718-724, 1989.
17. Tochner, Z., Kinsella, T. J., Rowland, J., and Glatstein, E. Treatment of unresectable sarcomas of adults with hyperfractionated irradiation and iododeoxyuridine. Br. J. Radiol., 19: 107-111, 1989.
18. Sondak, V. K., Robertson, J. M., Sussman, J. J., Saran, P. A., Chang, A. E., and Lawrence, T. S. Preoperative idoxuridine and radiation for large soft tissue sarcomas: clinical results with five-year follow-up. Ann. Surg. Oncol., 5: 106-112, 1998.
19. Knol, J., Walker, S., Robertson, J., Yang, Z., Deremer, S., Stetson, P., Ensminger, W., and Lawrence, T. Incorporation of 5-bromo-2′-deoxyuridine into colorectal liver metastases and liver in patient receiving a 7-day hepatic arterial infusion. Cancer Res., 55: 3687-3691, 1995.
20. Groves, M. D., Maor, M. H., Meyers, C., Kyritsis, A. P., Jaeckle, K. A., Yung, S. K. A., Sawaya, R. E., Hess, K., Bruner, J. M., Peterson, P., and Levin, V. A. A Phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by Procarbazine, Lomustine and Vincristine for glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys., 45: 127-135, 1999.
21. Russo, A., Gianni, L., Kinsella, T. J., Klecker, R. W., Jenkins, J., Rowland, J., Glatstein, E., Mitchell, J. B., Collins, J., and Myers, C. A pharmacologic evaluation of intravenous delivery of BUdR to patients with brain tumors. Cancer Res, 44: 1702-1705, 1984.
22. Speth, P. A. J., Kinsella, T. J., Belanger, K., Klecker, R. W., Smith, R., Rowland, J., and Collins, J. M. Fluorodeoxyuridine modulation of the incorporation of iododeoxyuridine into DNA of granulocytes: A Phase I and clinical pharmacological study. Cancer Res., 48: 2933-2937, 1988.
23. McGinn, C. J., Kunugi, K. A., Tutsch, K. D., Feierabend, C., Alberti, D., Lindstrom, M. J., Wilding, G., Arzoomanian, R. Z., and Kinsella, T. J. Leucovorin modulation of iododeoxyuridine radiosensitization: A Phase I study. Clin. Cancer Res., 2: 1299-1305, 1996.
24. Kinsella, T. J., Kunugi, K. A., Vielhuber, K., McCullough, W., Liu, S-H., and Cheng, Y-C. In vivo comparison of oral 5-iodo-2′-deoxyuridine and 5-iodo-2-pyrimidinone-2′-deoxyribose toxicity, pharmacokinetics, and DNA incorporation in athymic mouse tissues and a human colon cancer xenograft, HCT-116. Cancer Res., 54: 2695-2700, 1994.
25. Kinsella, T. J., Kunugi, K. A., Vielhuber, K. A., Fowler, J., Fitzsimmons, M., and Collins, J. M. Preclinical evaluation of 5-iodo-2′-pyrimidinone-2′-deoxyribose (IPdR) as a prodrug for IUdR-mediated tumor radiosensitization in mouse and human tissues. Clin. Cancer Res., 4: 99-109, 1998.
26. Lewandowski, G. A., and Cheng, T-C. Mechanism and mode of action of 5-iodo-2-pyrimidinone-2′deoxyribonucleoside, a potent anti-herpes simplex virus compound, in herpes simplex vims-infected cells. Mol. Pharmacol., 39: 27-33, 1990.
27. Chang, C-N., Doong, S-L., and Cheng, Y-C. Conversion of 5-iodo-2-pyrimidinone-2′-deoxyribose to 5-iodo-deoxyuridine by aldehyde oxidase: Implications in hepatotropic drug design. Biochem. Pharmacol., 43: 2269-2273, 1992.
28. Belanger, K., Collins, J. M., and Klecker, R. W., Jr. Technique for detection of DNA nucleobases by reverse-phase high performance liquid chromatography optimized for quantitative determination of thymidine substitution by iododeoxyuridine. J. Chromatogr., 417: 57-63, 1987.
29. SAS Institute, Inc. SAS/STAT User's Guide, Version 6. Cary, NC. SAS Institute, Inc., 1989.
30. Berry, S. E., Garces, C., Hwang, H-S., Kunugi, K., Myers, M., Davis, T. W., Boothman, D. A., and Kinsella, T. J. The mismatch repair protein, hMLH1, mediates 5-substituted halogenated thymidine analogue cytotoxicity, DNA incorporation, and radiosensitization in human colon cancer cells. Cancer Res., 59: 1840-1845, 1999.
31. Anonymous. Duke researchers link brain tumor drug resistance to mismatch repair deficiency. Compr. Ther., 23: 622-623, 1997.
32. Friedman, H., Johnson, S., Dong, Q., Schold, D., Rasheed, B., Bigner, S., Ali-Osman, F., Dolan, E., Colvin, O., Houghton, P., German, G., Drummond, J., Keir, S., Marcelli, S., Bigner, D., and Modrich, P. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res., 57: 2933-2936, 1997.
33. Sullivan, F. J., Herscher, L. L., Cook, J. A., Smith, J., Steinberg, S. M., Epstein, A. A., Mitchell, J. B., Kinsella, T. J., and Glatstein, E. National Cancer Institute (Phase II) study of high grade glioma treated with partial brain hyperfractionated radiation and iododeoxyuridine: Results in anaplastic astrocytoma. Int. J. Radiat. Oncol. Biol. Phys., 30: 583-590, 1994.
34. Kinsella, T. J., Collins, J., Rowland, J., Klecker, R., Wright, D., Katz, D., Steinberg, S. M., and Glatstein, E. Pharmacology, and Phase I/II study of continuous intravenous infusions of iododeoxyuridine and hyperfractionated radiotherapy in patients with glioblastoma multi-forme. J. Clin. Oncol., 6: 871-879, 1988.
35. Speth, P. A. J., Kinsella, T. J., Chang, A. E., Klecker, R. W., Jr., Belanger, K., and Collins, J. M. Selective incorporation of iododeoxyuridine into DNA of hepatic metastases versus normal human liver. Clin. Pharmacol. Ther., 44: 369-375, 1988.